Complement activation and cardiovascular disease

Hormone and Metabolic Research

Volumn 40, Issue 9, 2008, Pages 626-634

  Bjerre, M ^a   Hansen, T K ^a   Flyvbjerg, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Complement; Diabetes mellitus; Inflammation; Ischemia

Indexed keywords

APT 070; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBRINOLYTIC AGENT; MANNAN BINDING LECTIN; PEXELIZUMAB; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MOLECULAR DYNAMICS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; REVIEW; RHEUMATIC HEART DISEASE; TISSUE INJURY; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM; HUMANS;

EID: 53649096542     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1083786     Document Type: Review

References (116)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, MacDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sortie P, Steinberger J, Thorn T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171
2. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985; 37: 151-216
3. Muller-Eberhard H]. Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57: 321-347
4. Matsushita M, Endo Y, Hamasaki N, Fujita T. Activation of the lectin complement pathway by ficolins. Int Immunopharmacol 2001; 1: 359-363
5. Frederiksen PD, Thiel S, Larsen CB, Jensenius JC. M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand J Immunol 2005; 62: 462-473
6. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-578
7. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem 1987; 262: 7451-7454
8. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386: 506-510
9. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 1994; 15: 67-74
10. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33-42
11. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2: 1236-1239
12. Johnson E, Hetland G. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand J Immunol 1991; 33: 667-671
13. Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69-76
14. Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G, Berg K, Johnson E. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. Apmis 2001; 109: 73-78
15. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 2001; 24: 191-199
16. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 1999; 36: 261-268
17. Ghebrehiwet B, Peerschke El. cClq-R (calreticulin) and gClq-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol Immunol 2004; 41: 173-183
18. Oroszlan M, Daha MR, Cervenak L, Prohaszka Z, Fust G, Roos A. MBL and Clq compete for interaction with human endothelial cells. Mol Immunol 2007; 44: 1150-1158
19. Schmaier AH, Murray SC, Heda GD, Farber A, Kuo A, MacCrae K, Cines DB. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem 1989; 264: 18173-18179
20. Gulati P, Guc D, Lemercier C, Lappin D, Whaley K. Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium. Rheumatol Int 1994; 14: 13-19
21. Schlaf G, Demberg T, Beisel N, Schieferdecker HL, Gotze O. Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 2001; 38: 231-239
22. Berge V, Berge KE, Johnson E. Vitronectin modulates the expression of complement components of the terminal pathway synthesized by human umbilical vein endothelial cells in vitro. Apmis 1996; 104: 523-530
23. Berge V, Johnson E, Hogasen K. Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads. APMIS 1997; 105: 17-24
24. Hoppe HC, Wet BJ de, Cywes C, Daffe M, Ehlers MR. Identification of phosphatidylinositol mannoside as a mycobacterial adhesin mediating both direct and opsonic binding to nonphagocytic mammalian cells. Infect Immun 1997; 65: 3896-3905
25. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39: 287-324
26. Endemann DH, Schiffrin EL Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992
27. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4
28. Kyrou I, Tsigos C. Stress mechanisms and metabolic complications. Horm Metab Res 2007; 39: 430-438
29. Bellin C, Wiza DH de, Wiernsperger NF, Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 2006; 38: 732-739
30. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-210
31. Kostner KM, Fahti RB, Case C, Hobson P, Tate J, Marwick TH. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease, din Chim Acta 2006; 365: 129-134
32. Czermak BJ, Sarma V, Bless AIM, Schmal H, Friedl HP, Ward PA. In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol 1999; 162: 2321-2325
33. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am j Pathol 2001; 159: 1045-1054
34. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Bums JA, Meri S, Stahl GL. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000; 156: 1549-1556
35. Mold C, Mortis CA. Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation. Immunology 2001; 102: 359-364
36. Stahl GL, Reenstra WR, Frendl C. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ Res 1995; 76: 575-583
37. Lennon PF, Collard CD, Morrissey MA, Stahl GL. Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am J Physiol 1996; 270: H1924-H1932
38. Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol 2003; 162: 363-367
39. Arumugam TV, Shiels 1A, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia-reperfusion injury. Shock 2004; 21: 401-409
40. Khalil AA, Aziz FA, Hall JC. Reperfusion injury. Plast Reconstr Surg 2006; 117: 1024-1033
41. Yasuda M, Takeuchi K, Hiruma M, lida H, Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H et al. The complement system in ischemic heart disease. Circulation 1990; 81: 156-163
42. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103
43. lltumur K, Karabulut A, Toprak G, Toprak N. Complement activation in acute coronary syndromes. APM1S 2005; 113: 167-174
44. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000; 21: 1081-1090
45. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, Kramer J, Fust G, Kleiber M, Romics L, Varga L. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-389
46. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V, Nieminen MS, Lokki ML. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007; 99: 890-895
47. Engstrom G, Hedblad B, Janzon L, Lindgarde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur j Cardiovasc Prev Rehabil 2007; 14: 392-397
48. Best LG, Davidson M, North KE, MacCluer JW, Zhang Y, Lee ET, Howard BV, DeCroo S, Ferrell RE. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004; 109: 471-475
49. Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, Valdimarsson H. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med 2005; 201: 117-125
50. Norwood MG, Sayers RD, Roscher S, Lynch NJ, Sutton AJ, Schwaeble WJ. Consumption of mannan-binding lectin during abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2006; 31: 239-243
51. Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Froland SS, Mollnes TE, Dickstein K, Aukrust P. Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. J Card Fail 2006; 12: 659-663
52. Biezeveld MH, Geissler J, Weverling GJ, Kuipers IM, Lam J, Ottenkamp J, Kuijpers TW. Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease. Arthritis Rheum 2006; 54: 369-376
53. Schafranski MD, Stier A, Nisihara R, Messias-Reason IJ. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency. Clin Exp Immunol 2004; 138: 521-525
54. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971; 133: 885-900
55. Pinckard RN, O'Rourke RA, Crawford MH. Grover FS, MacManus LM, Ghidoni JJ, Storrs SB, Olson MS. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 1980; 66: 1050-1056
56. MacManus LM, Kolb WP, Crawford MH, O'Rourke RA, Grover FL, Pinckard RN. Complement localization in ischemic baboon myocardium. Lab Invest 1983; 48: 436-447
57. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, MacGeer PL. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res 1998; 82: 1224-1230
58. Ito W, Schafer HJ, Bhakdi S, Mask R, Hansen S, Schaarschmidt S, Schofer J, Hugo F, Hamdoch T, Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res 1996; 32: 294-305
59. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 1994; 144: 1357-1368
60. Vries B de. Walter SJ. Peutz-Kootstra CJ, Wolfs TG, Heum LW van, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004; 165: 1677-1688
61. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005; 175: 541-546
62. Moller-Kristensen M, Wang W, Ruseva M, Thiel S, Nielsen S, Takahashi K, Shi L, Ezekowitz A, Jensenius JC, Gadjeva M. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 2005; 61: 426-434
63. Crawford MH, Grover FL. Kolb WP, MacMahan CA, O'Rourke RA. Mac-Manus LM. Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988; 78: 1449-1458
64. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-1740
65. Pepys MB, Hirschfield CM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN. Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC. Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221
66. Niculescu F, Niculescu T, Rus H. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp Mol Pathol 2004; 76: 17-23
67. Rugonfalvi-Kiss S, Dosa E, Madsen HO, Endresz V, Prohaszka Z, Laki J, Karadi I. Gonczol E. Selmeci L, Romics L, Fust G, Entz L, Garred P. High rate of early restenosis after carotid eversion endarterectomy in homozygous carriers of the normal mannose-binding lectin genotype. Stroke 2005; 36: 944-948
68. Szeplaki G, Varga L. Laki J, Dosa E, Madsen HO, Prohaszka Z, Szabo A, Acsady G, Selmeci L, Garred P, Fust G. Entz L. Elevated complement C3 is associated with early restenosis after eversion carotid endarterectomy. Thromb Haemost 2006; 96: 529-534
69. Fiane AE, Videm V, Lingaas PS, Heggelund L, Nielsen EW, Geiran OR, Fung M, Mollnes TE. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation 2003; 108: 849-856
70. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 2006; 333: 475-480
71. Ryden L, Standl E, Bartnik M, Berghe G Van den, Betteridge J, Boer MJ de, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J. Tuomilehto J. Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P. Qiao Q, Priori SG, Blanc JJ, Budaj A, Camtn J, Dean V. Deckers J, Dickstein K, Lekakis J, MacGregor K, Metro M. Morais J. Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR. Graham I, Monteiro PF, Parhofer K, Pyorala K. Raz I, Schernthaner G, Volpe M, Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
72. Hansen HH, Joensen AM, Riahi S, Malczynski J, Molenberg D. Ravkilde J. Short and long-term outcome in diabetic patients with acute myocardial infarction in the invasive era. Scand Cardiovasc J 2007; 41: 19-24
73. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53: 1570-1576
74. Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 2006; 166: 2007-2013
75. Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, Hays AP, Halperin JA. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653-2661
76. Hansen TK. Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm Metab Res 2005; 37 (Suppl 1): 95-98
77. Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4857-4861
78. Saraheimo M, Forsblom C, Hansen TK, Teppo AM, Fagerudd J, Pettersson-Fernholm K, Thiel S, Tarnow L, Ebeling P, Flyvbjerg A, Groop PH. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005; 48: 198-202
79. Hansen TK, Tarnow L, AS A, Thiel S, Parving HH, Flyvbjerg A. Mannosebinding lectin genotype and serum concentrations predict mortality in type 1 diabetes. In 66th Scientific session of the American Diabetes Organisation. Washington, USA; 2006
80. Hovind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, Flyvbjerg A, Parving HH. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005; 54: 1523-1527
81. Ostergaard J, Thiel S, Gadjeva M, Hansen TK, Rasch R, Flyvbjerg A. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia 2007; 50: 1541-1549
82. Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2: 88-94
83. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259-2267
84. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: H448-H457
85. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation 2003; 108: 1176-1183
86. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190
87. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964-1970
88. Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 942-949; discussion 949-950
89. Mathew JP, Shernan SK, White WD, Fitch JC, Chen JC, Bell L, Newman MF. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke 2004; 35: 2335-2339
90. Verrier ED, Shernan SK, Taylor KM, Werf F Van de, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. Jama 2004; 291: 2319-2327
91. Haverich A, Shernan SK, Levy JH, Chen JC, Carrier M, Taylor KM, Werf F Van de, Newman MF, Adams PX, Todaro TG, Laan M van der, Verrier ED. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg 2006; 82: 486-492
92. Carrier M, Menasche P, Levy JH, Newman MF, Taylor KM, Haverich A, Chen JC, Shernan SK, Werf F Van de, Laan M van der, Todaro TG, Adams PX, Verrier ED. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg 2006; 131: 352-356
93. Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O'Neill W, Todaro TG, Vahanian A, Werf F Van de, Granger CB. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2005; 149: 402-407
94. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Werf F Van de. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43-51
95. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu DX. C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun 2007; 357: 446-452
96. Cicardi M, Zingale L, Zanchelli A, Pappalardo E, Cicardi B. Cl inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005; 27: 286-298
97. Asghar SS, Pasch MC. Therapeutic inhibition of the complement system. Y2K update. Front Biosci 2000; 5: E63-E81
98. Kirschfink M, Mollnes TE. Cl-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2001; 2: 1073-1083
99. Inderbitzin D, Beldi G, Avital I, Vinci G, Candinas D. Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human Cl inhibitor. Eur Surg Res 2004; 36: 142-147
100. Simoni MG De, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L. The powerful neuroprotective action of Cl-inhibitor on brain ischemia-reperfusion injury does not require Clq. Am J Pathol 2004; 164: 1857-1863
101. Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with Cl-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998; 24: 635-638
102. Tassani P, Kunkel R, Richter JA, Oechsler H, Lorenz HP, Braun SL, Eising GP, Haas F, Paek SU, Bauernschmitt R, Jochum M, Lange R. Effect of Cl-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 2001; 15: 469-473
103. Zwaan C de, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, Dieijen-Visser MP van, Hermens WT. Continuous 48-h Cl-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002; 23: 1670-1677
104. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi P, Ruvolo G. Beneficial effects of Cl esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007; 32: 326-332
105. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-151
106. Chavez-Cartaya RE, DeSola GP, Wright L, Jamieson NV, White DJ. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. Transplantation 1995; 59: 1047-1052
107. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, Carroll MC. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183: 2343-2348
108. Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 619-624
109. Lazar HL, Bao Y, Gaudiani J, Rivers S, Marsh H. Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 1999; 100: 1438-1442
110. Austen WC Jr. Kyriakides C, Favuzza J, Wang Y, Kobzik L, Moore FD Jr, Hechtman HB. Intestinal ischemia-reperfusion injury is mediated by the membrane attack complex. Surgery 1999; 126: 343-348
111. Lazar HL, Bokesch PM, Lenta F van, Fitzgerald C, Emmett C, Marsh HC Jr, Ryan U. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004; 110: 11274-11279
112. Lazar HL, Keilani T, Fitzgerald CA, Shapiro OM, Hunter CT, Shemin RJ, Marsh HCJr, Ryan US. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 2007; 116: 183-188
113. Li JS, Sanders SP, Perry AE, Stinnett SS, Jaggers J, Bokesch P, Reynolds L, Nassar R, Anderson PA. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J 2004; 147: 173-180
114. Zacharowski K, Otto Af, Ha/her G, Marsh HC Jr, Thiemermann C. Reduction of myocardial infarct size with sCRlsLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br J Pharmacol 1999; 128: 945-952
115. Huang J, Kim LJ. Mealey R, Marsh HCJr, Zhang Y, Tenner AJ, Connolly ESJr, Pinsky DJ. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285: 595-599
116. Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2005; 145: 1027-1034